Abstract:Background: Prostate cancer (PCa) is an age-associated malignancy with high morbidity and mortality rate, posing a severe threat to public health. Cellular senescence, a specialized cell cycle arrest form, results in the secretion of various inflammatory mediators. In recent studies, senescence has shown an essential role in tumorigenesis and tumor development, yet the extensive effects of senescence in PCa have not been systematically investigated. Here, we aimed to develop a feasible senescence-associated prognosis model for early identification and appropriate management in patients with PCa. Method: The RNA sequence results and clinical information available from The Cancer Genome Atlas (TCGA) and a list of experimentally validated senescence-related genes (SRGs) from the CellAge database were first obtained. Then, a senescence-risk signature related with prognosis was constructed using univariate Cox and LASSO regression analysis. We calculated the risk score of each patient and divided them into high-risk and low-risk groups in terms of the median value. Furthermore, two datasets (GSE70770 and GSE46602) were used to assess the effects of the risk model. A nomogram was built by integrating the risk score and clinical characteristics, which was further verified using ROC curves and calibrations. Finally, we compared the differences in the tumor microenvironment (TME) landscape, drug susceptibility, and the functional enrichment among the different risk groups. Results: We established a unique prognostic signature in PCa patients based on eight SRGs, including CENPA, ADCK5, FOXM1, TFAP4, MAPK, LGALS3, BAG3, and NOX4, and validated well prognosis-predictive power in independent datasets. The risk model was associated with age and TNM staging, and the calibration chart presented a high consistency in nomogram prediction. Additionally, the prognostic signature could serve as an independent prediction factor due to its high accuracy. Notably, we found that the risk score was positively associated with tumor mutation burden (TMB) and immune checkpoint, whereas negatively correlated with tumor immune dysfunction and exclusion (TIDE), suggesting that these patients with risk scores were more sensitive to immunotherapy. Drug susceptibility analysis revealed differences in the responses to general drugs (docetaxel, cyclophosphamide, 5-Fluorouracil, cisplatin, paclitaxel, and vincristine) were yielded between the two risk groups. Conclusion: Identifying the SRG-score signature may become a promising method for predicting the prognosis of patients with PCa and tailoring appropriate treatment strategies.

Identification of molecular subtypes and a prognostic signature based on chromatin regulators related genes in prostate cancer

Fifteen-MiRNA-Based Signature is a Reliable Prognosis-Predicting Tool for Prostate Cancer Patients.

Risk subtyping and prognostic assessment of prostate cancer based on consensus genes

Identification of cell differentiation trajectory-related gene signature to reveal the prognostic significance and immune landscape in prostate cancer based on multiomics analysis

Establishment of Novel Prostate Cancer Risk Subtypes and A Twelve-Gene Prognostic Model

Subtype and prognostic analysis of immunogenic cell death-related gene signature in prostate cancer

The Established Chemokine-Related Prognostic Gene Signature in Prostate Cancer: Implications for Anti-Androgen and Immunotherapies

Identification of a novel senescence-associated signature to predict biochemical recurrence and immune microenvironment for prostate cancer

Establishment of cancer-associated fibroblasts-related subtypes and prognostic index for prostate cancer through single-cell and bulk RNA transcriptome

Identification of a DNA Repair Gene Signature and Establishment of a Prognostic Nomogram Predicting Biochemical-Recurrence-Free Survival of Prostate Cancer

Identification of ARHGEF38, NETO2, GOLM1, and SAPCD2 Associated With Prostate Cancer Progression by Bioinformatic Analysis and Experimental Validation

Signature Panel of 11 Methylated Mrnas and 3 Methylated Lncrnas for Prediction of Recurrence-Free Survival in Prostate Cancer Patients

Novel Gene Signatures Predictive of Patient Recurrence-Free Survival and Castration Resistance in Prostate Cancer

Deciphering the role of zinc homeostasis in the tumor microenvironment and prognosis of prostate cancer

Development of a Novel Immune-Related Prognostic Signature for Prostate Cancer

Identification and Verification of an ALYREF-involved 5-Methylcytosine Based Signature for Stratification of Prostate Cancer Patients and Prediction of Clinical Outcome and Response to Therapies

Insights into immune microenvironment and therapeutic targeting in androgen-associated prostate cancer subtypes

Gene Expression Profiling Identifies Clinically Relevant Subtypes Of Prostate Cancer

Stroma-specific gene expression signature identifies prostate cancer subtype with high recurrence risk

Development and Verification of a Prostate Cancer Prognostic Signature Based on an Immunogenomic Landscape Analysis

Basement Membrane-Related Gene Signature to Predict Biochemical Recurrence in Patients with Prostate Cancer after Radical Prostatectomy